These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 6342356)

  • 1. Enzyme-induced asparagine and glutamine depletion and immune system function.
    Kafkewitz D; Bendich A
    Am J Clin Nutr; 1983 Jun; 37(6):1025-30. PubMed ID: 6342356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of blastogenesis by native and polyethylene glycol-modified asparaginases from Escherichia coli and Vibrio succinogenes.
    Bendich A; Kafkewitz D; Abuchowski A; Davis FF
    Immunol Commun; 1983; 12(3):273-84. PubMed ID: 6350165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibition of lymphocyte mitogenesis by asparaginase: a still unexplained phenomenon.
    Kafkewitz D; Bendich A
    Experientia; 1984 Nov; 40(11):1173-7. PubMed ID: 6389170
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of Acinetobacter glutaminase-asparaginase treatment on free amino acids in mouse tissues.
    Holcenberg JS; Tang E; Dolowy WC
    Cancer Res; 1975 May; 35(5):1320-5. PubMed ID: 1091350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological effects of native and polyethylene glycol-modified asparaginases from Vibrio succinogenes and Escherichia coli in normal and tumour-bearing mice.
    Bendich A; Kafkewitz D; Abuchowski A; Davis FF
    Clin Exp Immunol; 1982 Apr; 48(1):273-8. PubMed ID: 7044632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase-L-asparaginase.
    Abuchowski A; van Es T; Palczuk NC; McCoy JR; Davis FF
    Cancer Treat Rep; 1979 Jun; 63(6):1127-32. PubMed ID: 466651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
    Avramis VI; Panosyan EH
    Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase.
    Reinert RB; Oberle LM; Wek SA; Bunpo P; Wang XP; Mileva I; Goodwin LO; Aldrich CJ; Durden DL; McNurlan MA; Wek RC; Anthony TG
    J Biol Chem; 2006 Oct; 281(42):31222-33. PubMed ID: 16931516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the effects of asparaginase from Escherichia coli and a glutaminase-free asparaginase from Vibrio succinogenes on specific ell-mediated cytotoxicity.
    Durden DL; Distasio JA
    Int J Cancer; 1981 Jan; 27(1):59-65. PubMed ID: 7019106
    [No Abstract]   [Full Text] [Related]  

  • 10. L-asparaginase-mediated Therapy in L-asparagine Auxotrophic Cancers: A Review.
    Sindhu R; Manonmani HK
    Anticancer Agents Med Chem; 2022; 22(13):2393-2410. PubMed ID: 34994334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
    Chan WK; Horvath TD; Tan L; Link T; Harutyunyan KG; Pontikos MA; Anishkin A; Du D; Martin LA; Yin E; Rempe SB; Sukharev S; Konopleva M; Weinstein JN; Lorenzi PL
    Mol Cancer Ther; 2019 Sep; 18(9):1587-1592. PubMed ID: 31209181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the glutaminase activity of E. coli asparaginase in tissue culture.
    Oerkermann H; Hirschmann WD; Gross R
    Recent Results Cancer Res; 1970; 33():125-30. PubMed ID: 4949157
    [No Abstract]   [Full Text] [Related]  

  • 13. In silico engineering of L-asparaginase to have reduced glutaminase side activity for effective treatment of acute lymphoblastic leukemia.
    Ln R; Doble M; Rekha VP; Pulicherla KK
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):617-21. PubMed ID: 22042278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of sensitivity of cultured pancreatic carcinoma to asparaginase.
    Wu MC; Arimura GK; Yunis AA
    Int J Cancer; 1978 Dec; 22(6):728-33. PubMed ID: 363626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amino acid utilisation and deamination of glutamine and asparagine by Helicobacter pylori.
    Stark RM; Suleiman MS; Hassan IJ; Greenman J; Millar MR
    J Med Microbiol; 1997 Sep; 46(9):793-800. PubMed ID: 9291892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Asparaginase and glutaminase activity in Pseudomonas fluorescens in continuous cultivation].
    Eremenko VV; Zhukov AV; Nikolaev AIa
    Mikrobiologiia; 1975; 44(4):615-20. PubMed ID: 809640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive properties and circulating life of Achromobacter glutaminase-asparaginase covalently attached to polyethylene glycol in man.
    Abuchowski A; Davis FF; Davis S
    Cancer Treat Rep; 1981; 65(11-12):1077-81. PubMed ID: 7296553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asparaginase in the treatment of non-ALL hematologic malignancies.
    Emadi A; Zokaee H; Sausville EA
    Cancer Chemother Pharmacol; 2014 May; 73(5):875-83. PubMed ID: 24515335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutaminase-free asparaginase from vibrio succinogenes: an antilymphoma enzyme lacking hepatotoxicity.
    Distasio JA; Salazar AM; Nadji M; Durden DL
    Int J Cancer; 1982 Sep; 30(3):343-7. PubMed ID: 6752048
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the immunosuppressive effects of asparaginases from Escherichia coli and Vibrio succinogenes.
    Durden DL; Distasio JA
    Cancer Res; 1980 Apr; 40(4):1125-9. PubMed ID: 6986981
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.